GlassScriptPhysician profile
Indraneel Mogarala
NPI 1922025378
$2,090.08
in general payments reported to CMS, 2019-2025
21 companies · $67.88 in 2025
The $67.88 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $160 · 2021: $342 · 2022: $505 · 2023: $245 · 2024: $228 · 2025: $67.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.25 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $336.51 | 2019-2022 | |
| Akebia Therapeutics INC | $149.60 | 2022-2024 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $143.21 | 2022-2023 | |
| Horizon Therapeutics Plc | $130.68 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $127.94 | 2020 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 | |
| Mallinckrodt Enterprises LLC | $123.51 | 2019 | |
| Travere Therapeutics, INC. | $120.42 | 2023 | |
| Novo Nordisk INC | $117.12 | 2024 | |
| Mallinckrodt Hospital Products INC. | $112.47 | 2021 | |
| Calliditas Therapeutics US INC. | $105.86 | 2022 | |
| Aurinia Pharma U.S., INC. | $92.93 | 2022 | |
| Baxter Healthcare | $86.34 | 2019 | |
| Amgen INC. | $71.95 | 2024-2025 | Tavneos |
| Nxstage Medical, INC. | $69.45 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $42.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $39.27 | 2022-2024 | |
| Veloxis Pharmaceuticals, INC. | $35.51 | 2025 | Envarsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.77 | 2024 | Jardiance |
| Amicus Therapeutics, INC. | $21.18 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indraneel Mogarala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.